Mounjaro Savings Card Help
US$ 20.84
glp-1 drug news today 2025 access and 2026 health benefits: What consumers expect New survey data shows 59% of Americans support the Trump administration's plan to broaden access to GLP-1 drugs for weight-loss at discounted Weight-loss drug makers announce pricing
Description
Tirzepatide wins on efficacy among currently available options
How does Ozempic work compared to insulin
doi: 10.1210/jc.2003-030421 32 WynneKParkAJSmallCJPattersonMEllisSMMurphyKGet al
Key Takeaways In 2024, the market for GLP-1 receptor agonist generated a revenue of US$ 53.5 billion , with a CAGR of 17.5% , and is expected to reach US$ 268.4 billion by the year 2033
Choosing between Mounjaro and Wegovy
[DOI] [PMC free article] [PubMed] [Google Scholar] 63.Henrich MT, et al